Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that they have received a commitment from Innovation Fund Denmark to support the on-going clinical development of IPED2015.
The Innobooster grant will support the ongoing trial with up to 2 MDKK.
‘We are delighted to receive a commitment of support from Innovation Fund Denmark through the Innobooster program. It is a clear validation of Initiator Pharma and the quality of our IPED2015 program. We remain confident that IPED2015 will be a breakthrough therapy for the PDE5i